A Phase I Study of XJ103 in Chinese Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

December 24, 2024

Study Completion Date

March 6, 2025

Conditions

Pneumococcal Disease

Interventions

DRUG

XJ103 Injection

XJ103 is a humanized monoclonal antibody.

DRUG

Placebo

Placebo contains only excipients.

Trial Locations (1)

Shanghai General Hospita, Shanghai

All Listed Sponsors

lead

Starmab biologics（Shanghai）Co,.ltd

INDUSTRY